
# Advancements in Pharmaceutical Nanotechnology: Controlled, Targeted, and Sustained Drug Release Systems for Enhanced Therapeutic Efficacy and Clinical Translation

**Dr Olivia M Mehta [1*], Dr Lars T Turner [2]**
[1] Autonomous Agricultural Systems Lab, Purdue University, West Lafayette, IN, USA
[2] Autonomous Agri-Robotics Center, Central Institute of Agricultural Engineering, Bhopal, India

* Corresponding Author: **Dr Olivia M Mehta**

## Article Info

**P-ISSN:** 3051-3421
**E-ISSN:** 3051-343X
**Volume:** 04
**Issue:** 01
**Received:** 08-12-2022
**Accepted:** 10-01-2023
**Published:** 12-02-2023
**Page No:** 09-16

**Abstract**
Pharmaceutical nanotechnology has revolutionized drug delivery by enabling controlled, targeted, and sustained release of therapeutic agents, addressing limitations of conventional formulations including poor bioavailability, non-specific distribution, and rapid clearance. This review examines emerging trends in nanocarrier-based drug delivery systems designed to achieve precise spatial and temporal control over drug release kinetics. Key nanotechnological platforms discussed include polymeric nanoparticles, liposomes, solid lipid nanoparticles, dendrimers, metallic nanoparticles, and hybrid nanocarriers, each offering distinct advantages for specific therapeutic applications. Controlled release mechanisms encompass diffusion-mediated, degradation-controlled, and stimuli-responsive strategies, while targeting approaches exploit passive accumulation via enhanced permeability and retention effects and active targeting through ligand-receptor interactions. Sustained release systems provide prolonged therapeutic concentrations, reducing dosing frequency and improving patient compliance. Clinical applications span oncology, infectious diseases, chronic inflammatory conditions, and neurological disorders. Despite significant progress, challenges persist in scalability, manufacturing reproducibility, regulatory approval pathways, and long-term safety assessment. Future directions emphasize personalized nanomedicine, multi-functional nanocarriers integrating diagnostic and therapeutic modalities, and biomimetic systems mimicking natural biological structures. This review provides a comprehensive analysis of current pharmaceutical nanotechnology innovations, critically evaluating their translational potential and identifying research priorities for advancing controlled and targeted drug delivery toward routine clinical implementation.

**Keywords:** Pharmaceutical nanotechnology; Controlled drug release; Targeted drug delivery; Sustained release systems; Nanocarrier platforms; Nanomedicine

## 1. Introduction

The pharmaceutical industry faces persistent challenges in drug development, with approximately 40% of marketed drugs and 90% of pipeline candidates exhibiting poor aqueous solubility, leading to suboptimal bioavailability and therapeutic efficacy [1]. Conventional drug formulations often fail to achieve adequate concentrations at disease sites while causing systemic toxicity through non-specific distribution [2]. Additionally, rapid drug clearance necessitates frequent dosing, compromising patient adherence and treatment outcomes [3].

Pharmaceutical nanotechnology has emerged as a transformative approach to overcome these limitations by engineering nanocarrier systems ranging from 1 to 1000 nanometers that enable precise control over drug release kinetics, spatial distribution, and duration of action [4]. These nanocarriers protect therapeutic agents from premature degradation, enhance solubility of hydrophobic drugs, facilitate cellular uptake, and enable targeted delivery to specific tissues or cellular compartments [5, 6].

Controlled drug release refers to the ability to modulate release rates according to predetermined profiles, achieving consistent therapeutic concentrations [7]. Targeted delivery exploits unique pathophysiological characteristics of diseased tissues or utilizes molecular recognition mechanisms to concentrate drugs at specific anatomical sites [8]. Sustained release extends drug availability over prolonged periods, reducing dosing frequency and minimizing fluctuations between peak and trough plasma concentrations [9].

This review critically analyzes current advances in pharmaceutical nanotechnology for controlled, targeted, and sustained drug delivery, examining major nanocarrier platforms, release mechanisms, therapeutic applications, and translational challenges. The objective is to provide pharmaceutical scientists and clinicians with comprehensive insights into the state-of-the-art technologies shaping the future of nanomedicine and identify priority areas for further research and development.

## 2. Nanocarrier-Based Drug Delivery Systems

### 2.1. Polymeric Nanoparticles

Polymeric nanoparticles represent versatile platforms constructed from biodegradable or biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), chitosan, and polyethylene glycol (PEG) [10]. PLGA nanoparticles, approved by regulatory agencies for various applications, offer tunable degradation rates by adjusting the lactide-to-glycolide ratio, enabling customized release profiles from days to months [11]. Surface modification with PEG (PEGylation) reduces opsonization and extends circulation half-life by creating a hydrophilic barrier that minimizes protein adsorption and macrophage recognition [12].

Polymeric micelles self-assemble from amphiphilic block copolymers, forming core-shell structures with hydrophobic cores that solubilize poorly water-soluble drugs and hydrophilic coronas that provide steric stabilization [13]. Critical micelle concentrations determine stability under physiological conditions, with formulations designed to remain intact during circulation but release payloads upon reaching target sites through environmental triggers such as pH changes or enzymatic degradation [14].

### 2.2. Lipid-Based Nanocarriers

Liposomes, spherical vesicles composed of phospholipid bilayers enclosing aqueous compartments, represent the most clinically advanced nanocarrier platform with multiple FDA-approved formulations including Doxil® for ovarian cancer and Ambisome® for fungal infections [15]. Conventional liposomes exhibit rapid clearance by the mononuclear phagocyte system, prompting development of sterically stabilized "stealth" liposomes incorporating PEG-conjugated lipids that achieve circulation times exceeding 24 hours [16].

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) comprise solid lipid matrices at physiological temperature, offering enhanced stability compared to liquid lipid emulsions [17]. NLCs incorporate liquid lipids within solid matrices, creating imperfect crystalline structures that accommodate higher drug loading capacities and prevent drug expulsion during storage [18]. These systems enable sustained release through diffusion from the lipid matrix and gradual matrix erosion, with release kinetics modulated by lipid composition and particle size [19].

### 2.3. Emerging Nanocarrier Platforms

Dendrimers are highly branched, monodisperse macromolecules with precisely defined structures offering multivalent surface functionalization sites for drug conjugation and targeting ligands [20]. PAMAM (polyamidoamine) dendrimers exhibit generation-dependent properties, with higher generations providing increased drug loading through interior cavities and surface functional groups [21].

Metallic nanoparticles, particularly gold and iron oxide nanoparticles, combine therapeutic delivery with diagnostic capabilities, enabling theranostic applications [22]. Gold nanoparticles facilitate photothermal therapy through near-infrared light absorption while serving as drug carriers, whereas superparamagnetic iron oxide nanoparticles enable magnetic resonance imaging and magnetically guided targeting [23].

Carbon-based nanocarriers including carbon nanotubes and graphene oxide offer ultra-high surface areas for drug loading, exceptional mechanical strength, and unique optical properties [24]. However, concerns regarding biodegradability and long-term biocompatibility require comprehensive safety evaluation before clinical translation [25].

Table 1 summarizes major nanocarrier systems and their pharmaceutical applications, while Table 2 presents physicochemical characteristics influencing drug release kinetics.

## 3. Mechanisms of Controlled, Targeted, and Sustained Release

### 3.1. Controlled Release Kinetics

Controlled drug release from nanocarriers occurs through multiple mechanisms including diffusion, degradation, swelling, and stimuli-responsive release (Figure 2) [26]. Diffusion-controlled systems follow Fick's laws, with release rates determined by drug solubility, diffusion coefficient through the carrier matrix, and surface area-to-volume ratio [27]. Matrix systems exhibit square-root-of-time dependent release kinetics, while reservoir systems surrounded by rate-controlling membranes achieve zero-order release profiles maintaining constant drug concentrations [28].

Degradation-controlled release depends on polymer hydrolysis or enzymatic cleavage, with bulk erosion occurring throughout the matrix and surface erosion proceeding layer-by-layer [29]. PLGA undergoes bulk hydrolysis through ester bond cleavage, with acidic degradation products autocatalyzing further breakdown and creating initial lag phases followed by accelerated release [30].

Stimuli-responsive "smart" nanocarriers respond to endogenous triggers (pH, redox potential, enzymes) or exogenous stimuli (temperature, light, magnetic fields) [31]. pH-sensitive systems exploit acidic tumor microenvironments (pH 6.5-6.8) and endosomal compartments (pH 5.0-6.0) through incorporation of ionizable groups or acid-labile linkages [32]. Redox-responsive carriers utilize disulfide bonds cleaved by elevated glutathione concentrations in cytoplasm, enabling intracellular drug release [33].

### 3.2. Targeting Strategies

Passive targeting leverages the enhanced permeability and retention (EPR) effect arising from fenestrated tumor vasculature and impaired lymphatic drainage, allowing preferential accumulation of nanoparticles between 10-200

nm in solid tumors (Figure 3) [34]. However, EPR heterogeneity across tumor types and between patients limits universal applicability, with recent studies questioning its clinical relevance in human cancers [35].

Active targeting employs surface-conjugated ligands recognizing overexpressed receptors on target cells, enhancing cellular internalization through receptor-mediated endocytosis [36]. Common targeting moieties include folate for folate receptors on cancer cells, transferrin for transferrin receptors, antibodies against tumor-associated antigens, and peptides such as RGD sequences binding αvβ3 integrins on angiogenic endothelium [37, 38].

Cell-penetrating peptides (CPPs) derived from viral proteins or synthetic sequences facilitate membrane translocation and intracellular delivery through direct penetration or endocytic pathways [39]. Dual-targeting strategies combining vascular targeting with cellular targeting enhance tumor penetration and therapeutic efficacy [40].

### 3.3. Sustained Drug Delivery Approaches

Sustained release extends drug availability from single administrations through depot formation, gradual dissolution, or controlled degradation [41]. Injectable long-acting formulations based on PLGA microspheres provide therapeutic concentrations for weeks to months, exemplified by Risperdal Consta® for schizophrenia delivering risperidone over two weeks [42].

Nanoparticle-based ocular drug delivery systems overcome rapid tear clearance and corneal barrier limitations, with nanocarriers suspended in thermosensitive gels that undergo sol-gel transition at ocular surface temperature, prolonging residence time [43]. Intravitreal nanoparticle injections provide sustained intraocular drug levels for treating posterior segment diseases including age-related macular degeneration and diabetic retinopathy [44].

Figure 2 illustrates key mechanisms governing controlled and sustained release from nanocarrier systems.

## 4. Therapeutic Applications

### 4.1. Cancer Therapy

Nanomedicine has profoundly impacted oncology, with nanocarrier formulations enhancing therapeutic indices of cytotoxic agents through tumor-selective delivery and reduced systemic toxicity [45]. Doxil®, a PEGylated liposomal doxorubicin formulation, demonstrates significantly reduced cardiotoxicity compared to free doxorubicin while maintaining antitumor efficacy in ovarian cancer, multiple myeloma, and Kaposi's sarcoma [46].

Abraxane®, an albumin-bound paclitaxel nanoparticle formulation, eliminates toxic solubilizing agents required for conventional Taxol® while enhancing tumor delivery through albumin receptor-mediated transcytosis across endothelial barriers [47]. Clinical trials demonstrate superior response rates and progression-free survival in metastatic breast cancer and non-small cell lung cancer [48].

Combination therapy using nanocarriers co-delivering multiple drugs addresses resistance mechanisms and achieves synergistic effects [49]. Ratiometric co-delivery maintaining optimal drug ratios throughout circulation and at tumor sites enhances efficacy compared to separate administration of individual agents [50].

### 4.2 Infectious and Chronic Diseases

Lipid-based nanocarriers improve antifungal therapy through enhanced drug solubilization and reduced nephrotoxicity, with liposomal amphotericin B (AmBisome®) becoming standard treatment for invasive fungal infections. Nanoparticle-based antiretroviral therapy for HIV achieves sustained drug levels in viral reservoir sites including lymphoid tissues and the central nervous system, potentially enabling dose reduction and improved adherence.

Tuberculosis treatment benefits from nanocarrier-mediated delivery targeting infected macrophages and providing sustained drug release, addressing challenges of lengthy treatment regimens and intracellular mycobacterial persistence. Inhaled nanoparticle formulations deliver drugs directly to pulmonary sites of infection while minimizing systemic exposure.

Chronic inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease represent emerging applications for targeted nanocarriers delivering anti-inflammatory agents to sites of inflammation. RGD-conjugated nanoparticles target activated endothelium in inflamed joints, while orally administered nanoparticles with pH-sensitive coatings release drugs in the colonic environment.

Table 3 presents therapeutic applications of nanotechnology-based drug delivery across various disease areas.

## 5. Challenges and Future Perspectives

### 5.1. Formulation Challenges

Manufacturing reproducibility remains a critical challenge, with nanoparticle characteristics highly sensitive to processing parameters including mixing rates, temperature, and component ratios. Batch-to-batch variability in particle size distribution, drug loading, and release kinetics complicates scale-up from laboratory to commercial production. Implementation of quality-by-design principles incorporating real-time process monitoring and feedback control enhances manufacturing consistency.

Long-term stability of nanocarrier formulations requires careful optimization of storage conditions and excipient selection to prevent aggregation, drug leakage, and chemical degradation. Lyophilization with cryoprotectants preserves nanoparticle integrity during storage but may alter reconstitution characteristics.

### 5.2. Scale-Up, Regulatory, and Clinical Translation Issues

Scaling production from milligrams to kilograms while maintaining nanoparticle quality attributes necessitates transition from batch to continuous manufacturing technologies. Microfluidic synthesis platforms enable precise control over mixing and reaction conditions, producing uniform nanoparticles suitable for clinical applications.

Regulatory pathways for nanomedicines remain incompletely defined, with agencies requiring comprehensive physicochemical characterization, pharmacokinetic profiling, and toxicological assessment. The complex nature of nanocarriers as drug-device combination products complicates regulatory classification and approval requirements.

Clinical translation faces challenges including limited predictive value of preclinical models, heterogeneity of EPR effects in human tumors, and insufficient understanding of long-term nanoparticle fate and potential accumulation in off-target organs. Companion diagnostics identifying patients

most likely to benefit from nanoparticle-based therapies could enhance clinical trial success rates.

### 5.3. Future Research Directions

Personalized nanomedicine tailoring nanocarrier characteristics to individual patient physiology and disease characteristics represents a promising frontier. Integration of artificial intelligence and machine learning algorithms accelerates nanocarrier design by predicting structure-activity relationships and optimizing formulation parameters. Biomimetic nanocarriers camouflaging synthetic materials with natural cell membranes evade immune recognition while inheriting targeting properties of source cells. Erythrocyte membrane-coated nanoparticles demonstrate prolonged circulation, while cancer cell membrane-coated particles exhibit homotypic targeting to tumors.

Multi-functional theranostic nanocarriers integrating therapeutic delivery with real-time imaging enable treatment monitoring and personalized dose adjustment. Biodegradable nanoparticles that completely eliminate from the body address long-term safety concerns associated with persistent nanomaterials.

Table 4 summarizes advantages, limitations, and translational challenges of pharmaceutical nanocarriers, while Figure 1 provides a comprehensive overview of nanocarrier platforms for controlled, targeted, and sustained drug delivery, and Figure 3 illustrates targeting strategies in nanotechnology-based drug delivery.

## 6. Figure




**Fig 1:** Overview of Pharmaceutical Nanocarriers for Controlled, Targeted, and Sustained Drug Delivery




**Fig 2:** Mechanisms of Controlled and Sustained Drug Release from Nanocarrier Systems




**Fig 3:** Targeting Strategies in Nanotechnology-Based Drug Delivery (Passive vs Active Targeting)

## 7. Tables

**Table 1:** Major Nanocarrier Systems and Their Pharmaceutical Applications

| Nanocarrier Type | Size Range (nm) | Key Components | Drug Loading Mechanism | Primary Applications |
|---|---|---|---|---|
| Liposomes | 50-500 | Phospholipids, cholesterol | Hydrophobic: lipid bilayer; Hydrophilic: aqueous core | Cancer, fungal infections, vaccines |
| Polymeric nanoparticles | 10-1000 | PLGA, PLA, chitosan, PEG | Encapsulation, adsorption, conjugation | Cancer, inflammation, gene delivery |
| Solid lipid nanoparticles | 50-1000 | Solid lipids, surfactants | Incorporation into lipid matrix | Oral/topical delivery, brain targeting |
| Dendrimers | 1-100 | PAMAM, PPI | Interior encapsulation, surface conjugation | Cancer, gene delivery, imaging |
| Polymeric micelles | 10-100 | Amphiphilic block copolymers | Hydrophobic core incorporation | Cancer, poorly soluble drugs |
| Metallic nanoparticles | 1-100 | Gold, silver, iron oxide | Surface adsorption, conjugation | Theranostics, photothermal therapy, imaging |
| Carbon nanotubes | 1-100 (diameter) | Carbon | Surface functionalization | Drug/gene delivery, biosensing |

**Table 2:** Physicochemical Characteristics of Common Nanocarriers Influencing Drug Release

| Parameter | Effect on Drug Release | Optimal Range/Characteristics | Clinical Relevance |
|---|---|---|---|
| Particle size | Smaller particles: faster release due to higher surface area | 10-200 nm for EPR effect | Tissue penetration, biodistribution |
| Surface charge | Affects protein adsorption, cellular uptake | Near-neutral to slightly negative | Circulation time, targeting |
| Hydrophobicity | Determines plasma protein binding, opsonization | Hydrophilic corona (PEGylation) | Stealth properties, stability |
| Drug loading | Higher loading may cause burst release | 5-20% w/w for sustained release | Dose reduction, efficacy |
| Polymer molecular weight | Higher MW: slower degradation and release | PLGA: 10-100 kDa | Release duration control |
| Crystallinity | Amorphous: faster release; Crystalline: slower | Depends on therapeutic need | Storage stability |
| Drug-polymer interaction | Strong interaction: sustained release | Ionic, H-bonding, hydrophobic | Release predictability |

**Table 3:** Therapeutic Applications of Nanotechnology-Based Drug Delivery Systems

| Disease Area | Nanocarrier Type | Drug/Agent | Targeting Strategy | Clinical Status | Key Benefit |
|---|---|---|---|---|---|
| Breast cancer | Albumin nanoparticles | Paclitaxel (Abraxane®) | Passive (EPR) + albumin receptor | FDA approved | Improved efficacy, reduced toxicity |
| Ovarian cancer | PEGylated liposomes | Doxorubicin (Doxil®) | Passive (EPR) | FDA approved | Reduced cardiotoxicity |
| Kaposi's sarcoma | Liposomes | Daunorubicin (DaunoXome®) | Passive (EPR) | FDA approved | Tumor-selective delivery |
| Fungal infections | Liposomes | Amphotericin B (AmBisome®) | Organ distribution | FDA approved | Reduced nephrotoxicity |
| Age-related macular degeneration | Polymeric implants | Fluocinolone acetonide | Intravitreal sustained release | FDA approved | Prolonged efficacy, reduced injections |
| Schizophrenia | PLGA microspheres | Risperidone (Consta®) | Depot formation | FDA approved | Bi-weekly dosing |
| Multiple myeloma | Liposomes | Doxorubicin | Passive targeting | FDA approved | Enhanced therapeutic index |
| Hepatitis C | Lipid nanoparticles | siRNA | Hepatocyte targeting | Clinical trials | Gene silencing |
| Solid tumors | Polymeric micelles | Paclitaxel (Genexol-PM®) | Passive (EPR) | Approved (South Korea) | Solvent-free formulation |

**Table 4:** Advantages, Limitations, and Translational Challenges of Pharmaceutical Nanocarriers

| Aspect | Advantages | Limitations | Translational Challenges | Mitigation Strategies |
|---|---|---|---|---|
| Efficacy | Enhanced bioavailability, targeted delivery, reduced off-target toxicity | Variable EPR effect, heterogeneous tumor penetration | Patient selection, tumor heterogeneity | Companion diagnostics, imaging biomarkers |
| Manufacturing | Precise size control, versatile platforms | Batch-to-batch variability, complex scale-up | GMP compliance, reproducibility | Microfluidics, continuous processing, QbD |
| Stability | Protection from degradation | Aggregation, drug leakage during storage | Long-term shelf-life | Lyophilization, optimized excipients |
| Safety | Reduced systemic toxicity | Unknown long-term effects, accumulation concerns | Immunogenicity, complement activation | Biodegradable materials, thorough toxicology studies |
| Regulatory | Established approval pathways (liposomes) | Lack of standardized characterization methods | Complex drug-device classification | Harmonized guidelines, collaborative efforts |
| Cost | Potential for dose reduction | Expensive manufacturing, specialized equipment | Economic viability, reimbursement | Process optimization, generic development |
| Pharmacokinetics | Prolonged circulation, controlled release | Non-linear PK, accelerated blood clearance | Predictive modeling difficulties | Population PK studies, PBPK modeling |

## 8. Conclusion

Pharmaceutical nanotechnology has fundamentally transformed drug delivery, enabling unprecedented control over release kinetics, biodistribution, and therapeutic targeting. The diverse array of nanocarrier platforms—from clinically established liposomes to emerging biomimetic systems—offers tailored solutions for specific therapeutic challenges across oncology, infectious diseases, and chronic conditions. Controlled release mechanisms incorporating diffusion, degradation, and stimuli-responsive strategies provide temporal control, while passive and active targeting approaches achieve spatial selectivity. Sustained release formulations reduce dosing frequency and improve patient compliance.

Despite significant progress, translational challenges including manufacturing scalability, regulatory uncertainty, and incomplete understanding of nanoparticle-biological interactions require continued research efforts. Future directions emphasizing personalized nanomedicine, multi-functional theranostic platforms, and biomimetic designs promise to expand clinical applications and improve therapeutic outcomes. As the field matures, pharmaceutical nanotechnology is poised to become integral to standard clinical practice, offering patients more effective, safer, and convenient treatment options across diverse disease sta

## 9. References


1. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442-453.
2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
4. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
5. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124.
6. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
7. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm. 2008;364(2):328-343.
8. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-146.
9. Langer R. Drug delivery and targeting. Nature. 1998;392(6679 Suppl):5-10.
10. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522.
11. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-1397.
12. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28-51.
13. Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev. 2018;118(14):6844-6892.
14. Yokoyama M. Polymeric micelles as drug carriers: their lights and shadows. J Drug Target. 2014;22(7):576-583.
15. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
16. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-436.
17. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
18. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine (Lond). 2016;12(1):143-161.
19. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305-313.
20. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm

Bioallied Sci. 2014;6(3):139-150.
21. Caminade AM, Turrin CO, Laurent R, Ouali A, Delavaux-Nicot B. Dendrimers: towards catalytic, material and biomedical uses. Chichester: John Wiley & Sons; 2011.
22. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, *et al*. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193.
23. Sharifi S, Seyednejad H, Laurent S, Atyabi F, Saei AA, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for *in vivo* molecular and cellular imaging. Contrast Media Mol Imaging. 2015;10(5):329-355.
24. Liu Z, Tabakman S, Welsher K, Dai H. Carbon nanotubes in biology and medicine: *in vitro* and *in vivo* detection, imaging and drug delivery. Nano Res. 2009;2(2):85-120.
25. Ou L, Song B, Liang H, Liu J, Feng X, Deng B, *et al*. Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms. Part Fibre Toxicol. 2016;13(1):57.
26. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, *et al*. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.
27. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2-3):139-157.
28. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—a review. Int J Pharm. 2011;415(1-2):34-52.
29. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-2663.
30. Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, *et al*. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325-341.
31. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.
32. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152-167.
33. Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release. 2011;152(1):2-12.
34. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging *in vivo*. Adv Drug Deliv Rev. 2013;65(1):71-79.
35. Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244(Pt A):108-121.
36. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25.
37. Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134.
38. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater. 2012;24(28):3747-3756.
39. Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38(4):406-424.
40. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, *et al*. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328(5981):1031-1035.
41. Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. J Am Chem Soc. 2016;138(3):704-717.
42. Hoy SM. Risperidone long-acting injection: a review of its use in the treatment of schizophrenia. Drugs. 2013;73(18):1991-2016.
43. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-360.
44. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47-64.
45. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017;42(12):742-755.
46. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, *et al*. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-449.
47. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, *et al*. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317-1324.
48. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, *et al*. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-7803.
49. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, *et al*. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano. 2010;4(8):4539-4550.
50. Wang J, Mao W, Lock LL, Tang J, Sui M, Sun W, *et al*. The role of micelle size in tumor accumulation, penetration, and treatment. ACS Nano. 2015;9(7):7195-7206.